NASDAQ: LIFEEthos Technologies Inc Stock
$16.85+0.00 (+0%)
Updated Jan 30, 2026
LIFE Price
$16.85
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$15.51
52 Week High
$19.00
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.72
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LIFE Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LIFE's potential to beat the market
- LIFE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Property & Casualty Insurance
Industry Rating
B
LIFE
RankedUnranked of 17
RankedUnranked of 17
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.45 | B | |
| $42.05 | B | |
| $29.49 | C |
Be the first to know about important LIFE news, forecast changes, insider trades & much more!
LIFE News
Overview
Due Diligence Score
–
Industry Average (39)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LIFE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIFE's short-term assets ($234.87M) exceed its short-term liabilities ($108.06M)
Short-term Liabilities Financials
LIFE's short-term assets ($234.87M) exceed its long-term liabilities ($25.17M)
Long-term Liabilities Financials
LIFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LIFE due diligence checks available for Premium users.
Valuation
LIFE's financial health
Profit margin
Revenue
$93.8M
Net Income
$15.9M
Profit Margin
16.9%
Assets to liabilities
Assets
$488.3M
Liabilities
$133.2M
Debt to equity
-2.72
LIFE's short-term assets ($234.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIFE's short-term assets ($234.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LIFE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.2M
Investing
$1.9M
Financing
-$5.1M
LIFE vs Property & Casualty Insurance Stocks
Ethos Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.